home / stock / cydy / cydy news

CYDY News and Press, CytoDyn Inc From 03/29/19

Stock Information
Company Name: CytoDyn Inc
Stock Symbol: CYDY
Market: OTC
Website: cytodyn.com
Menu
CYDY CYDY Quote CYDY Short CYDY News CYDY Articles CYDY Message Board
Get CYDY Alerts

News, Short Squeeze, Breakout and More Instantly...
CYDY - NanoString Technologies Fundraising Signals Inflection Point In Strategy

Editor's note: Seeking Alpha is proud to welcome Theodore Zucconi as a new contributor. It's easy to become a Seeking Alpha contributor and earn money for your best investment ideas. Active contributors also get free access to the SA PRO archive. Click here to find out more » NanoStri...
CYDY - CytoDyn's PRO 140 continues to show positive action in HIV

CytoDyn ( OTCQB:CYDY ) announces that new data show that weekly doses of 525 mg and 700 mg of leronlimab (PRO 140) in HIV-1-positive patients produced a 90% response rate in patients who passed the first 10 weeks of monotherapy without virologic failure. More news on: CytoDyn Inc., Healt...

CYDY - CytoDyn's Monotherapy Trial with Leronlimab (PRO 140) Exceeds Expectations

New data suggests that 525 mg dose and 700 mg dose responders’ rates are approximately 90% for those HIV patients who pass first 10 weeks of monotherapy without virologic failure CytoDyn has engaged top CCR5 expert, Bruce Patterson M.D., former Medical Director of Virology at Sta...

CYDY - Progenics: Why I Finally Decided To Buy

I have been hesitant about buying into Progenics Pharmaceuticals ( PGNX ) due to my insufficient knowledge about the advancements of radiopharmaceuticals in the oncology arena. Perhaps it is all the hype of immuno-oncology and the rise of gene therapy that caused me to believe that radiopharma...
CYDY - CytoDyn Reaches Historical Milestone, Submits First of Three Sections of BLA to FDA for Leronlimab (PRO 140) as a Combination Therapy for HIV

VANCOUVER, Washington, March 18, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, to...

CYDY - CytoDyn Reports Significant Reduction in Breast Cancer Tumor Metastasis in Preclinical Study and Requests FDA Fast Track Designation for Leronlimab (PRO 140) in Metastatic-Triple Negative Breast Cancer (mTNBC)

VANCOUVER, Washington, March 11, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , (“CytoDyn” or the “Company”) a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced th...

CYDY - FDA Grants Rolling Review for CytoDyn's Planned BLA for Investigational HIV Therapy Leronlimab (PRO 140)

VANCOUVER, Washington, March 04, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY) , a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, today announced that the FDA has reviewed and accepted Cyto...
CYDY - CytoDyn to Present New Data from Study of Investigational HIV Therapy Leronlimab (PRO 140), a Long-Acting, Single-Agent Maintenance Therapy at CROI 2019

VANCOUVER, Washington, Feb. 27, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY ), a late stage biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, today announced that data from its study of leronlimab (PRO 140) is schedule...

CYDY - CytoDyn: What To Do When It's Too Good To Be True?

CytoDyn ( CYDY ) is a full fledged penny stock with an exciting story to tell. The premise of this posting is that it has so much sizzle that it is entirely too hot to handle. I am staying away, at least for the time being. CytoDyn plans on its paradigm shifting PRO 140 rapidly taking a majo...

CYDY - Leronlimab (PRO 140) reduces by more than 98% human breast cancer metastasis in mouse xenografts for over 6 weeks

VANCOUVER, Washington, Feb. 20, 2019 (GLOBE NEWSWIRE) -- CytoDyn Inc. (OTC.QB: CYDY), a biotechnology company developing a novel humanized CCR5 monoclonal antibody for multiple therapeutic indications, announces that it was able to reduce by more than 98% the incidence of human breast cance...
Previous 10 Next 10